Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials testing the oral JAK inhibitor in ulcerative colitis met their primary endpoints, but Pfizer is awaiting the results of another Phase III maintenance study before filing for a label extension.
You may also be interested in...
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.